BioTech

Spark Therapeutics (ONCE), a commercial gene therapy company, announced Friday that the European Commission has granted marketing authorization for LUXTURNA (voretigene neparvovec).

DUBLIN, March 11, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Ne

Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Sandoz drives differentiated portfolio with deal to commercialize new treatment fo

Source: globenewswire.com MacroGenics Inc. has announced positive results from SOPHIA, a Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. Margetuximab is...

ROCKLAND, Mass. and NEW YORK, May 14, 2019 /PRNewswire/ -- BAVENCIO is the first anti-PD-L1 in combination with INLYTA approved by FDA for first-line treatmen

Source: globenewswire.com Columbia based, Osiris Therapeutics (NASDAQ: OSIR), is engaged in the research, development, and manufacturing of regenerative medicine products intended to improve the health...

Source: globenewswire.com The European Commission has given approval to Roche’s drug MabThera (rituximab). This drug helps treat adults with moderate to severe pemphigus vulgaris (PV),...

Source: www.novartis.com The US Food and Drug Administration (FDA) has granted Novartis Breakthrough Therapy designation for its investigational therapy crizanlizumab (SEG101). This revolutionary treatment is...

Although it was probably not in serious jeopardy, Bristol-Myers Squibb’s shareholders voted today to approve the acquisition of Celgene Corporation for about $74 billion.